Hematology Frontier

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7–10, 2024, in San Diego, USA. As the largest international academic conference in hematology, it showcased cutting-edge research and the latest advancements in drug development, representing the highest level of academic achievement in the field. Severe aplastic anemia (SAA) remains a challenging condition to treat, with a poor prognosis, making it a focal point for research. At this year's ASH meeting, Dr. Fengkui Zhang and his team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences presented a study (Abstract 304) exploring the efficacy of combining the novel thrombopoietin receptor agonist (TPO-RA), Hetrombopag, with immunosuppressive therapy (IST) for treating SAA. The study demonstrated promising results. In an exclusive interview, Hematology Frontier delved into the findings and implications of this research with Professor Zhang. Below is a detailed summary and analysis of the study and interview.

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights of this year’s conference were seven groundbreaking studies from Dr. Xiaowen Tang’s team at The First Affiliated Hospital of Soochow University. These included two oral presentations (O270, O683) and five poster presentations (P3384, P3493, P4197, P4284, P4836). Covering key areas such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), CAR-T cell therapy, and hematopoietic stem cell transplantation (HSCT), the research showcased the team's innovative contributions to hematology. Hematology Frontier interviewed Professor Tang on-site to explore the clinical significance of the two oral presentations, injecting new vitality into the advancement of hematology.

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights was a poster presentation (P4196) by Dr. Ying Wang from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. This study explored the efficacy and safety of CD19 CAR-T therapy in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), demonstrating its potential to improve remission and survival rates. Hematology Frontier interviewed Professor Wang to analyze the study's key findings and the future prospects of CD19 CAR-T therapy.

Despite significant advancements in the treatment of multiple myeloma (MM) in recent years, particularly with the advent of innovative therapies, the prognosis for certain high-risk patient groups remains suboptimal. This is especially true for newly diagnosed multiple myeloma (NDMM) patients with renal impairment. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7–10, Wen Gao, Professor of Hematology at Beijing Chaoyang Hospital, presented findings from a study on the efficacy of the SPVD quadruple therapy as a first-line treatment for NDMM patients with renal impairment. The research offers a novel and promising solution to a pressing clinical challenge. Hematology Frontier invited Dr. Wen Gao to provide an in-depth analysis of this study and its significant implications for clinical practice.

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest and most comprehensive international conference in hematology, successfully took place from December 7 to 10, 2024, in San Diego, USA. This annual event attracts numerous hematology experts and scholars worldwide to exchange ideas and discuss significant breakthroughs in the field. During this year's ASH conference, the Chinese American Hematologist and Oncologist Network (CAHON) held its 2024 Winter Symposium. Experts shared insights, reviewed past accomplishments, and presented cutting-edge advancements in areas ranging from basic research to clinical applications. The event not only fostered academic exchanges and knowledge sharing but also played a pivotal role in advancing the diagnosis and treatment of related diseases while promoting global professional collaboration.

The 66th Annual Meeting of the American Society of Hematology (ASH) successfully concluded in San Diego, USA, from December 7–10, 2024. As the largest and most comprehensive international academic conference in the field of hematology, it attracts global experts and scholars each year to discuss and exchange views on the latest research advancements. During this year’s ASH meeting, the Chinese American Hematologist and Oncologist Network (CAHON) successfully held its Winter Symposium. Hematology frontier invited Dr. JingZhou Hou, CAHON President and a professor at the University of Pittsburgh Medical Center, to share insights on CAHON’s founding mission, highlights from this Winter Symposium, and details of his three research studies (including one oral presentation and two posters) presented at ASH.

The 2024 American Society of Hematology (ASH) Annual Meeting took place in San Diego from December 7 to 10, attracting the global hematology community's attention. As one of the most prestigious international events in the field, this conference has drawn keen interest from researchers and clinicians worldwide, including those in China. To provide timely updates on the most significant daily highlights, Oncology Frontier – Hematology Frontier launched the special column ASH Daily News Highlights. Hosted by Dr. Jun Zhu from Peking University Cancer Hospital, the column features daily expert interviews, offering firsthand insights into the conference. We were honored to connect with Dr. Huiqiang Huang from the Lymphoma Center of Sun Yat-sen University Cancer Hospital to discuss the latest research in lymphoma presented at the conference.

The 66th American Society of Hematology (ASH) Annual Meeting was held in San Diego, USA, from December 7–10, 2024. Renowned as the largest and most comprehensive international academic event in the field of hematology, the conference gathers leading experts and researchers worldwide to discuss and exchange groundbreaking advancements in hematology. At this year's meeting, the research led by Dr. Jing Pan from Beijing GoBroad Boren Hospital garnered significant attention, with two studies related to CAR-T therapy (abstracts 964 and 3466) being featured. To provide a deeper understanding of these pivotal findings, Hematology Frontier interviewed Dr. Jing Pan, who shared insights on these studies and the broader topic of CAR-T therapy. Below is a summary of the research and interview.